The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.
0734 GMT - Ipsen's deal to buy Kartos Therapeutics for up to $1.75 billion seems in line with its merger-and-acquisition strategy, adding to its pipeline a late-stage hemato-oncology asset that could hit the market in 2028, RBC Capital Markets' Natalia Webster and Charles Weston say in a research note. The French drugmaker typically looks for late-stage assets with reduced risk that complement its existing portfolio, the analysts say. Kartos is due to release next year results of a late-stage clinical trial for drug candidate navtemadlin as an add-on treatment for rare blood cancer myelofibrosis, RBC says. There is unmet need and commercial opportunity in this disease given that ruxolitinib--the standard of care--has discontinuation rates of 50 to 75% within three years, the analysts add. Ipsen shares rise 1.9%. (adria.calatayud@wsj.com)
0235 GMT - UltraGreen.ai stands to benefit from greater indocyanine green demand across both established and emerging surgical procedures, Phillip Securities' Hashim Osman says in commentary. ICG usage is expected to increase by double digits across the majority of procedures using fluorescence-guided surgery by 2028, the analyst says. The main driver is ICG becoming a standard of care, with major surgical societies incorporating ICG into their clinical guidelines, the analyst adds. The Singapore-based company supplies imaging agents such as indocyanine green for fluorescence-guided surgery. The brokerage initiates coverage of the stock with a buy rating and a target price of US$1.92. Shares are 0.8% higher at US$1.24. (ronnie.harui@wsj.com)
2342 GMT - Bell Potter raises its price target on Neuren Pharmaceuticals by 6.8% to A$23.50/share after a key European regulator reverses its initial rejection of the trofinetide treatment for Rett Syndrome. Drug advisory body CHMP has decided, after a re-examination, to adopt a positive recommendation. Analyst Thomas Wakim says it's likely that trofinetide, also known as Daybue, will be approved in Europe in around two months. "The addition of Daybue European sales adds A$2.00/share to our NPV valuation based on current forecasts," Bell Potter says. Neuren ended last week at A$12.20. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
June 29, 2026 04:20 ET (08:20 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
Comments